The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.
An international research collaboration led by UC San Francisco researchers has identified a genetic variant common in Latina women that protects against breast cancer.
The variant, a difference in just one of the 3 billion “letters” in the human genome known as a single-nucleotide polymorphism (SNP), originates from indigenous Americans and confers significant protection from breast cancer, particularly the more aggressive estrogen receptor—negative forms of the disease, which generally have a worse prognosis.
“The effect is quite significant,” said Elad Ziv, MD, professor of medicine and senior author of the study. “If you have one copy of this variant, which is the case for approximately 20% of US Latinas, you are about 40% less likely to have breast cancer. If you have 2 copies, which occurs in approximately 1% of the US Latina population, the reduction in risk is on the order of 80%.”
Link to the report: http://bit.ly/1yavsLN
Source: UCSF
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
February 29th 2024ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
Read More